3B Blackbio DX Ltd

3B Blackbio Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

3B Blackbio DX Ltd

₹ 1,139 2.28%
03 Jun - close price
kilpest.com BSE: 532067 NSE: 3BBLACKBIO
About

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Key Points

Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit

Website BSE NSE
  • Market Cap ₹ 977 Cr.
  • Current Price ₹ 1,139
  • High / Low ₹ 1,750 / 1,084
  • Stock P/E 19.8
  • Book Value ₹ 372
  • Dividend Yield 0.35 %
  • ROCE 22.4 %
  • ROE 16.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 95.7% CAGR over last 5 years

Cons

  • Company has high debtors of 162 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
17.77 13.21 18.57 16.96 21.99 17.51 26.57 23.43 23.02 20.36 27.91 24.38 24.63
9.61 6.52 9.91 7.37 11.84 7.17 11.48 8.47 13.56 8.77 12.07 9.91 13.35
Operating Profit 8.16 6.69 8.66 9.59 10.15 10.34 15.09 14.96 9.46 11.59 15.84 14.47 11.28
OPM % 45.92% 50.64% 46.63% 56.54% 46.16% 59.05% 56.79% 63.85% 41.09% 56.93% 56.75% 59.35% 45.80%
1.19 2.96 2.75 2.47 4.15 3.68 3.43 3.01 4.91 4.31 3.91 4.63 1.30
Interest 0.05 0.02 0.04 0.02 0.04 0.01 0.03 0.02 0.03 0.01 0.01 0.02 0.00
Depreciation 0.28 0.18 0.22 0.20 0.27 0.22 0.22 0.22 0.20 0.22 0.22 0.22 0.29
Profit before tax 9.02 9.45 11.15 11.84 13.99 13.79 18.27 17.73 14.14 15.67 19.52 18.86 12.29
Tax % 35.92% 20.95% 23.95% 22.30% 35.31% 22.19% 22.61% 24.14% 34.65% 20.55% 23.46% 23.33% 39.46%
5.78 7.47 8.48 9.21 9.06 10.73 14.14 13.45 9.24 12.46 14.94 14.46 7.45
EPS in Rs 7.70 9.95 11.29 10.73 10.56 12.50 16.48 15.67 10.77 14.52 17.41 16.85 8.68
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
18 16 13 16 12 14 14 16 59 71 91 97
17 15 12 14 12 14 16 17 30 36 41 44
Operating Profit 1 1 1 1 0 -0 -1 -1 30 35 50 53
OPM % 7% 7% 8% 7% 4% -2% -8% -8% 50% 50% 55% 55%
0 0 0 0 1 1 4 10 7 12 15 14
Interest 1 1 1 1 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 1 1 1 1
Profit before tax 0 0 0 1 0 1 2 8 36 46 64 66
Tax % 21% 23% 14% 9% 2% 0% 18% 5% 26% 26% 26% 26%
0 0 0 1 0 1 2 8 26 34 48 49
EPS in Rs 0.34 0.30 0.36 0.81 0.67 0.81 2.29 10.67 35.19 39.86 55.41 57.46
Dividend Payout % 0% 0% 83% 61% 74% 86% 392% 98% 8% 8% 7% 9%
Compounded Sales Growth
10 Years: 20%
5 Years: 47%
3 Years: 18%
TTM: 7%
Compounded Profit Growth
10 Years: 74%
5 Years: 96%
3 Years: 23%
TTM: 4%
Stock Price CAGR
10 Years: 61%
5 Years: 21%
3 Years: 42%
1 Year: -31%
Return on Equity
10 Years: 17%
5 Years: 19%
3 Years: 17%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 6 6 6 6 6 7 7 7 9 9 9 9
Reserves 4 5 5 9 9 13 15 16 188 219 264 310
7 7 8 6 6 4 2 3 2 1 0 0
7 6 5 5 5 4 4 5 16 21 24 31
Total Liabilities 25 24 24 26 27 28 29 32 214 250 297 350
3 3 3 2 2 2 2 3 7 7 6 7
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 1 1 1 4 4 4 102 128 167 188
22 21 21 22 23 22 23 25 105 116 124 155
Total Assets 25 24 24 26 27 28 29 32 214 250 297 350

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 1 0 -1 0 1 3 8 21 28 44 43
-0 -0 0 -0 -0 -2 -0 -2 -8 -20 -34 -20
-0 -1 -0 1 -0 1 -2 -6 -3 -4 -3 -7
Net Cash Flow 0 0 0 0 -0 0 1 0 10 5 8 16
Free Cash Flow 0 1 0 -1 0 1 3 6 20 28 44 41
CFO/OP 21% 87% 26% -63% 107% -458% -264% -663% 102% 112% 119% 111%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 271 303 371 332 426 382 358 337 206 188 142 162
Inventory Days 128 121 190 108 176 116 88 81 154 144 122 102
Days Payable 204 190 237 115 156 108 95 108 63 65 24 21
Cash Conversion Cycle 196 234 323 326 447 390 351 311 297 267 240 243
Working Capital Days 183 218 279 328 427 438 422 391 248 225 174 182
ROCE % 6% 5% 6% 6% 4% 4% 9% 34% 32% 22% 26% 22%

Insights

In beta
Mar 2019 Mar 2023 Mar 2024 Mar 2025
Domestic Lab/Hospital Reach
Number

Log in to view insights

Please log in to see hidden values.

Login
Global Presence (Countries)
Number
MDx Research & Development (R&D) Spend as % of Turnover
%
Number of Agrochemical Dealers
Number
Number of Molecular Diagnostic Assays Developed
Number
Capacity Utilization (Diagnostic Kits)
%
Number of Agrochemical Products (Biologicals)
Number
Number of Agrochemical Products (Chemicals)
Number
Domestic Customer Access (India Cities)
Number
Long-term Reagent-Rental Contracts
Number
Molecular Diagnostics (MDx) Market Share in India
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
38.43% 38.43% 38.43% 41.29% 41.28% 41.28% 41.28% 41.28% 41.28% 41.28% 41.27% 40.94%
3.06% 3.16% 3.38% 2.97% 3.28% 3.27% 2.68% 2.49% 2.70% 2.64% 2.57% 2.57%
0.00% 0.82% 1.18% 1.89% 1.96% 1.96% 1.74% 1.60% 1.76% 1.82% 1.87% 1.98%
58.50% 57.60% 56.99% 53.85% 53.48% 53.48% 54.29% 54.64% 54.28% 54.26% 54.27% 54.50%
No. of Shareholders 12,41610,51310,0889,7539,3999,58610,16610,34510,61910,70910,50710,616

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jun 2026
    Transcript
    PPT
    REC
  • Jun 2026
    Transcript
    PPT REC
  • Feb 2026
    Transcript PPT REC
  • Nov 2025
    Transcript
    AI Summary
    PPT
  • Aug 2025
    Transcript PPT REC
  • May 2025
    Transcript
    AI Summary
    PPT
  • Feb 2025
    Transcript
    AI Summary
    PPT
  • Nov 2024
    Transcript
    AI Summary
    PPT
  • Aug 2024
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript
    AI Summary
    PPT
  • Feb 2024
    Transcript
    AI Summary
    PPT
  • Nov 2023
    Transcript
    AI Summary
    PPT
  • Aug 2023
    Transcript
    AI Summary
    PPT
  • May 2023
    Transcript
    AI Summary
    PPT
  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Nov 2022
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT
  • Aug 2022
    Transcript
    AI Summary
    PPT
  • May 2022
    Transcript
    AI Summary
    PPT
  • Feb 2022
    Transcript
    AI Summary
    PPT
  • Nov 2021
    Transcript
    AI Summary
    PPT
  • Sep 2021
    Transcript
    AI Summary
    PPT
  • Jul 2021
    Transcript
    AI Summary
    PPT
  • Jun 2021
    Transcript
    AI Summary
    PPT
  • Feb 2021
    Transcript
    AI Summary
    PPT
  • Feb 2021
    Transcript
    AI Summary
    PPT
  • Nov 2020
    Transcript
    AI Summary
    PPT
  • Sep 2020
    Transcript
    AI Summary
    PPT
  • Jul 2020
    Transcript
    AI Summary
    PPT
  • Jun 2020
    Transcript
    AI Summary
    PPT
  • Feb 2020
    Transcript
    AI Summary
    PPT
  • Nov 2019
    Transcript
    AI Summary
    PPT
  • Jul 2019
    Transcript
    AI Summary
    PPT
  • May 2019
    Transcript
    AI Summary
    PPT
  • Jan 2019
    Transcript
    AI Summary
    PPT
  • Nov 2018
    Transcript
    AI Summary
    PPT
  • Aug 2018
    Transcript
    AI Summary
    PPT
  • May 2018
    Transcript
    AI Summary
    PPT
  • Feb 2018
    Transcript
    AI Summary
    PPT
  • Nov 2017
    Transcript
    AI Summary
    PPT
  • Jul 2017
    Transcript
    AI Summary
    PPT
  • Feb 2017
    Transcript
    AI Summary
    PPT